New drug combo trial offers hope for rare lung cancer patients
NCT ID NCT07357623
Summary
This study is testing whether adding standard chemotherapy to a newer drug called surufatinib works better than surufatinib alone for treating a rare type of lung tumor called a pulmonary neuroendocrine tumor. Researchers will enroll 96 adults who haven't had prior systemic treatment for this cancer. The main goal is to see if the combination helps shrink tumors more effectively and for a longer time, while carefully monitoring safety.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PULMONARY NEUROENDOCRINE TUMOR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Peking Union Medical College Hospital
NOT_YET_RECRUITINGBeijing, Beijing Municipality, 100000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Shanghai chest hospital
RECRUITINGShanghai, Shanghai Municipality, 200000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
The First Affiliated Hospital Of Anhui Medical University
NOT_YET_RECRUITINGHefei, Anhui, 230000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
The First Affiliated Hospital of Zhengzhou University
NOT_YET_RECRUITINGZhengzhou, Henan, 450000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.